MTX-COVAB / Memo Therap - LARVOL DELTA

Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening. (PubMed, Viruses) - "Discovery of SARS-CoV-2-specific antibodies was performed upon display of antibodies on the surface of HEK293T cells by antigen-specific sorting using binding to the SARS-CoV-2 spike and absence of binding to huACE2 as the sort criteria...MTX-COVAB completed GMP manufacturing by the end of 2020, but clinical development was stopped when the Omicron variant emerged, a variant that proved to be detrimental to all monoclonal antibodies already approved. The present study describes the capabilities of the DROPZYLLA® platform to identify antibodies of high virus-neutralizing capacity rapidly and directly."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19. (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Memo Therapeutics AG | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19. (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Memo Therapeutics AG | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jun 2022 ➔ Sep 2022

Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19. (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Memo Therapeutics AG | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19. (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Memo Therapeutics AG

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A phase 1 study assessing the safety and tolerability of MTx-COVAB36 in healthy volunteers. (ANZCTR) - P1 | N=32 | Not yet recruiting | Sponsor: Memo Therapeutics AG

New P1 trial • Infectious Disease • Novel Coronavirus Disease

Memo Therapeutics AG’s Antibody Against SARS-CoV-2 Demonstrates Potent Therapeutic and Prophylactic Activity in Advanced COVID-19 Disease Model (Businesswire) - "Memo Therapeutics AG,...announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has demonstrated outstanding efficacy in an animal model of the infection...'Our GMP material will be ready in December 2020, enabling us to start clinical studies in March 2021,' said Dr. Karsten Fischer, CEO of Memo Therapeutics AG."

New trial • Preclinical • Novel Coronavirus Disease